Non Alcoholic Steatohepatitis clinical trials

Explore recruiting non alcoholic steatohepatitis clinical trials.

Recruiting non alcoholic steatohepatitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Alcoholic Steatohepatitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Reducing Non-Alcoholic Steatohepatitis

Czechia

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Romania, Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

Poland, Belgium, Austria, Hungary, Italy, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis

Spain, Belgium, Austria, Czechia, Portugal, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

MK-7480 Multiple Ascending Dose Study in Healthy Participants

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

Bulgaria, Germany, Spain, Poland, Portugal, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non Alcoholic Steatohepatitis trials by city

Non Alcoholic Steatohepatitis in Toronto Non Alcoholic Steatohepatitis in Vancouver Non Alcoholic Steatohepatitis in Montreal Non Alcoholic Steatohepatitis in Calgary Non Alcoholic Steatohepatitis in Edmonton Non Alcoholic Steatohepatitis in Ottawa Non Alcoholic Steatohepatitis in Winnipeg Non Alcoholic Steatohepatitis in Quebec City Non Alcoholic Steatohepatitis in Hamilton Non Alcoholic Steatohepatitis in Kitchener Non Alcoholic Steatohepatitis in London Non Alcoholic Steatohepatitis in Halifax Non Alcoholic Steatohepatitis in New York Non Alcoholic Steatohepatitis in Los Angeles Non Alcoholic Steatohepatitis in Chicago Non Alcoholic Steatohepatitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease